Breast cancer patients tended to exhibit lower CD4+ TSCM counts than both groups (CD4+ TSCMs: 1.52 ± 0.70 cells/μL) but CD8+ TSCMs tended to be higher among patients compared to survivors (CD8+ TSCMs: 0.49 ± 0.18 cells/μL) but similar to healthy women. Here, CD8A is linked to breast carcinoma.